G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
Category: News and updates
G-BA assessments of new indications
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1
Highlights of G-BA’s annual report 2020
The G-BA has recently published its annual report from last year, 2020. Key statistics on the early benefit assessments The number of
IQWiG published a new method assessment
The whole IQWiG project can be accessed here.
8 NUB assessments of high-risk medical devices (§ 137h)
Hospitals can treat patients with novel methods as soon as they become available. The treatment is reimbursed by SHI funds within the